Author

Nicholas F. Reuter

Observed names: N F Reuter, N. F. Reuter, N. Reuter, Nicholas Reuter

Institution: Coborn Cancer Center

Observed institutions: Roswell Park Comprehensive Cancer Center, Geisinger Medical Center, Mayo Clinic, North Central Cancer Treatment Group, St. Cloud Hospital, Centracare, Coborn Cancer Center, Mayo Clinic in Florida, CentraCare Health System, Duluth Clinic, New York University

OpenAlex ID: A5085137338

Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.

1995 · R M Goldberg, C L Loprinzi, et al. · Journal of Clinical Oncology · 184

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

2012 · Thanyanan Reungwetwattana, Julian R. Molina, et al. · Journal of Thoracic Oncology · 44

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

2010 · Sumithra J. Mandrekar, Yingwei Qi, et al. · Journal of Thoracic Oncology · 38

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study

2007 · A. A. Adjei, J. R. Molina, et al. · Journal of Clinical Oncology · 37

Transdermal fentanyl in the management of cancer pain in ambulatory patients: An open-label pilot study

1996 · Julie E. Hammack, James A. Mailliard, et al. · Journal of Pain and Symptom Management · 25

Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer a collaborative north central cancer treatment group/mayo clinic phase ii study

1990 · James E. Krook, Charles L. Loprinzi, et al. · Cancer · 22

D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC

2007 · Julian R. Molina, Sumithra J. Mandrekar, et al. · Journal of Thoracic Oncology · 21

Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure

1985 · James N. Ingle, Stephanie J. Green, et al. · American Journal of Clinical Oncology · 14

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules

2004 · A. A. Adjei, S. Nair, et al. · Journal of Clinical Oncology · 10

Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation

2008 · S. J. Mandrekar, S. L. Hillman, et al. · Journal of Clinical Oncology · 4

A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma

1996 · Thomas M. Pisansky, Charles L. Loprinzi, et al. · Cancer · 3

A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC)

2005 · E. A. Johnson, R. S. Marks, et al. · Journal of Clinical Oncology · 1

FDA Regulation of Prescription of Controlled Substances

1999 · Nicholas Reuter · Humana Press eBooks

Works count: 13

Citation count: 403

H-index: 9

I10-index: 9